BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

...adaptive Phase Ib/IIa trial of the ruthenium-based small molecule that selectively inhibits stress-induced upregulation of GRP78...
...bile duct cancers. Financial terms were not disclosed. Targets GRP78 (glucose-regulated protein, 78kDa; HspA5) - Heat shock 70 kDa protein 5...
BioCentury | Apr 3, 2020
Distillery Therapeutics

Depletion of the mitochondrial chaperone HspA9 for BRAF-mutant melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Reducing production of the mitochondrial chaperone HspA9 could treat BRAF-mutant melanoma. In melanoma patients, high tumor levels of HspA9 mRNA were associated with poor survival. In two human melanoma cell...
BioCentury | Nov 21, 2019
Tools & Techniques

Measuring real-time PK/PD by monitoring aberrant chaperone activity

A Memorial Sloan Kettering Cancer Center team developed an imaging probe for aberrant protein networks that could guide more optimal drug dosing and scheduling earlier in development. In cancer, tumor biopsy collection as well as...
BioCentury | Nov 14, 2019
Targets & Mechanisms

New roles for HDACs in the cytoplasm and muscle disorders

While HDACs are known for their epigenetic function, NIBR researchers have discovered cytoplasmic HDAC4 substrates involved in muscle physiology. The findings suggest blocking HDAC4 deacetylation activity could treat muscle atrophy and other musculoskeletal disorders. HDACs...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Meeting the burden

...4362 Protein folding Protein folding DNAJ; AR-V7 DNAJ isoforms AR-V7-expressing CRPC 2901 HSPA4 HSP70; AR-V7 HSPA5...
BioCentury | Oct 24, 2017
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Mouse and fruit fly studies suggest promoting HspA8 expression could help treat ALS. In muscle samples from mouse and Drosophila models of ALS overexpressing TDP-43 with the ALS-associated point mutations...
BioCentury | Oct 13, 2017
Financial News

Intezyne raises $10M in series A

...is a ruthenium-based small molecule that inhibits stress-induced expression of heat shock 70 kDa protein 5 (glucose-regulated protein, 78kDa; GRP78; HspA5...
...monitoring technology, and total joint replacement implants. Intezyne Technologies Inc. , Tampa, Fla. Jennie Walters IT-139 IT-141 Intezyne Technologies Inc. Heat shock 70 kDa protein 5 (glucose-regulated protein, 78kDa) (GRP78) (HspA5) Topoisomerase...
BioCentury | Oct 6, 2017
Financial News

Intezyne raises $10M series A

...is a ruthenium-based small molecule that inhibits stress-induced expression of heat shock 70 kDa protein 5 (glucose-regulated protein, 78kDa; GRP78; HspA5...
...focus on bone screws, medication adherence monitoring technology, and total joint replacement implants. Jennie Walters IT-139 IT-141 Intezyne Technologies Inc. Heat shock 70 kDa protein 5 (glucose-regulated protein, 78kDa) (GRP78) (HspA5) Topoisomerase...
BioCentury | Aug 17, 2017
Targets & Mechanisms

GRP-THINK AT THE BBB

...mAb against GRP78 or bispecific comprising the GRP78 antibody and a therapeutic mAb Concept Targeting GRP78...
...bispecific antibody. BACE1 - β-site APP-cleaving enzyme 1; CLDN5 - Claudin 5; GRP78 (HspA5) - Heat shock 70 kDa protein 5...
...Aquaporin-4 BACE1 - β-site APP-cleaving enzyme 1 CLDN5 - Claudin 5 GRP78 (HspA5) - Heat shock 70 kDa protein 5...
BioCentury | Jun 29, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 47